Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finalized Consent Decree For Allston Largely In Line With Genzyme's Expectations

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech will pay an upfront disgorgement of $175 million from past profits on drugs made at Allston; must transfer all fill/finish out of troubled facility by end of November.
Advertisement

Related Content

Fabrazyme Patients Ask FDA To Retool Genzyme's Product Distribution Plan
Fabrazyme Patients Ask FDA To Retool Genzyme's Product Distribution Plan
Genzyme Jumps First Consent Decree Hurdle
Genzyme Jumps First Consent Decree Hurdle
Good News For A Change At Genzyme: Consent Decree Finalized Without Surprises, Lumizyme Approved By FDA Ahead Of Schedule
Good News For A Change At Genzyme: Consent Decree Finalized Without Surprises, Lumizyme Approved By FDA Ahead Of Schedule
Genzyme, Industry Analysts Relieved By Particulars In Draft Consent Decree
Genzyme's Manufacturing Problems Lead To Enforcement Action By FDA
Genzyme's Manufacturing Problems Lead To Enforcement Action By FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS070669

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel